HealthNotableSingle-sourceDeveloping
5.2
AstraZeneca heart disease trial failure raises efficacy concerns for silencer drug class
STAT NewsLO·GB·2 days ago
Pharmaceutical firms are advancing new hair loss treatments, with market analysts positioning the sector as a potential successor to the GLP-1 drug boom. The commercial viability remains speculative as clinical outcomes and regulatory approval timelines are not yet finalized.